FY2025 EPS Estimate for Beam Therapeutics Cut by Analyst

Beam Therapeutics Inc. (NASDAQ:BEAM) – Analysts at Cantor Fitzgerald cut their FY2025 EPS estimates for Beam Therapeutics in a note issued to investors on Wednesday, February 26th. Cantor Fitzgerald analyst R. Bienkowski now anticipates that the company will post earnings per share of ($3.55) for the year, down from their previous forecast of ($3.34). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share.

Beam Therapeutics (NASDAQ:BEAM) last issued its earnings results on Tuesday, February 25th. The company reported ($1.09) EPS for the quarter, topping the consensus estimate of ($1.25) by $0.16. The business had revenue of $30.00 million during the quarter, compared to analysts’ expectations of $16.47 million. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. Beam Therapeutics’s revenue was down 90.5% compared to the same quarter last year. During the same quarter last year, the firm posted $1.73 earnings per share.

Several other research analysts have also weighed in on BEAM. Wedbush reiterated an “outperform” rating and issued a $57.00 price objective on shares of Beam Therapeutics in a research note on Monday, January 13th. Guggenheim reaffirmed a “buy” rating and issued a $78.00 price target on shares of Beam Therapeutics in a research note on Thursday. Leerink Partnrs raised Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. Sanford C. Bernstein raised Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 7th. Finally, Leerink Partners raised Beam Therapeutics from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $27.00 to $39.00 in a research note on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $50.90.

Beam Therapeutics Price Performance

NASDAQ BEAM opened at $27.11 on Friday. The firm has a market capitalization of $2.24 billion, a price-to-earnings ratio of -15.40 and a beta of 1.92. The company has a 50 day simple moving average of $27.23 and a 200-day simple moving average of $25.92. Beam Therapeutics has a 52-week low of $20.84 and a 52-week high of $45.79.

Insider Activity at Beam Therapeutics

In other news, insider Christine Bellon sold 1,241 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $24.68, for a total value of $30,627.88. Following the completion of the sale, the insider now directly owns 102,968 shares of the company’s stock, valued at approximately $2,541,250.24. This represents a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John M. Evans sold 30,000 shares of the business’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $26.75, for a total transaction of $802,500.00. Following the transaction, the chief executive officer now directly owns 908,659 shares in the company, valued at $24,306,628.25. This trade represents a 3.20 % decrease in their position. The disclosure for this sale can be found here. 4.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Beam Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Wealthfront Advisers LLC bought a new stake in shares of Beam Therapeutics in the 4th quarter worth approximately $41,000. GF Fund Management CO. LTD. bought a new position in Beam Therapeutics in the fourth quarter worth $43,000. Sterling Capital Management LLC boosted its stake in Beam Therapeutics by 816.0% during the fourth quarter. Sterling Capital Management LLC now owns 2,409 shares of the company’s stock worth $60,000 after buying an additional 2,146 shares in the last quarter. Blue Trust Inc. increased its holdings in Beam Therapeutics by 84.0% in the 3rd quarter. Blue Trust Inc. now owns 3,135 shares of the company’s stock valued at $73,000 after buying an additional 1,431 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Beam Therapeutics by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,981 shares of the company’s stock valued at $75,000 after buying an additional 524 shares in the last quarter. 99.68% of the stock is owned by institutional investors and hedge funds.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.